Torrent Pharmaceuticals Share Price Target 2026: Analyst Forecast, Bull & Bear Case

Torrent Pharmaceuticals (NSE: TORNTPHARM) trades at Rs 2,850 as of April 2026 — against a 52-week high of Rs 3,700 and a 52-week low of Rs 2,600. The analyst consensus 12-month Torrent Pharmaceuticals share price target is Rs 3,300–3,700, implying 16–30% upside. This article covers the key catalysts, risks, financial positioning, and a structured bull/bear case share price target for 2026 and beyond.

Get free SEBI-registered analyst research on Torrent Pharmaceuticals on Univest.

Torrent Pharmaceuticals Share Price — Snapshot

Track Torrent Pharmaceuticals live on the Univest Screener — fundamentals, FII/DII flows, analyst ratings.

About Torrent Pharmaceuticals

Click Here — Get Free Investment Predictions on Univest.

Torrent Pharmaceuticals is India’s fifth-largest pharma company — with branded generic leadership in cardiology (Nikoran, Dilzem), CNS, and GI segments in India. Germany and Brazil contribute 25% of revenue from established generic markets.

Key Growth Catalysts — Torrent Pharmaceuticals Share Price Target

Tap to Access Best Research Pieces on Univest.

1. India Branded Generic Cardiology

India Branded Generic Cardiology — 8% Market Share in Rs 50,000 Cr Market

2. Germany Acquisition

Germany Acquisition — Integrating Hensinki Pharma Adding EUR 40 Mn Revenue

3. MR Expansion

MR Expansion — 10,000 Field Force Targeting Tier 2 Markets

Key Risks to Watch

Risk 1: Germany generic price erosion on key portfolio products

Germany generic price erosion on key portfolio products

Risk 2: Limited US branded generic pipeline vs peers

Limited US branded generic pipeline vs peers

Torrent Pharmaceuticals Share Price Target 2026

Subscribe to Univest Pro for premium analyst research on Torrent Pharmaceuticals.

Short-Term Target (3–6 Months)

In the near term, Torrent Pharmaceuticals is expected to trade in the Rs 2,600–Rs 3 range pending Q4 FY26 results and FY27 guidance clarity. The 52-week low of Rs 2,600 is the primary downside reference for position management.

12-Month Analyst Consensus Target

The analyst consensus 12-month Torrent Pharmaceuticals share price target is Rs 3,300–3,700 — implying 16–30% upside from Rs 2,850. This consensus assumes the primary catalysts materialise and macro conditions stabilise. These are analyst projections, not guaranteed returns. Check live targets on the Univest Screener.

Long-Term Target (FY27–FY28)

The Torrent Pharmaceuticals long-term target is Rs 4,500 in the bull case for FY27–28 — achievable if earnings delivery is consistent and catalysts accelerate. The bear case of Rs 2,200 represents the risk scenario if primary headwinds persist.

Download the Univest iOS App or Univest Android App for live Torrent Pharmaceuticals price and SEBI-registered analyst alerts.

Conclusion

Torrent Pharmaceuticals at Rs 2,850 offers risk-reward of 16–30% to the 12-month analyst consensus of Rs 3,300–3,700. The bull case of Rs 4,500 is achievable on full catalyst delivery; the bear case Rs 2,200 is the downside reference. Track Q4 FY26 results and FY27 management guidance as the primary near-term catalysts for validating the Torrent Pharmaceuticals share price target thesis.

For more stock research, visit Univest Blogs.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available data as of April 2026. Investments in securities are subject to market risk. Please consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q: What is Torrent Pharmaceuticals share price target for 2026?

The 12-month analyst consensus Torrent Pharmaceuticals share price target is Rs 3,300–3,700, implying 16–30% upside from Rs 2,850. Bull case is Rs 4,500; bear case is Rs 2,200. These are analyst projections, not guaranteed returns.

Q: What is Torrent Pharmaceuticals’s current share price?

Torrent Pharmaceuticals (NSE: TORNTPHARM) trades at Rs 2,850 as of April 2026. 52-week high is Rs 3,700; 52-week low is Rs 2,600. Market cap is Rs 96,000 Cr.

Q: Is Torrent Pharmaceuticals a good buy at current levels?

This article does not constitute investment advice. Torrent Pharmaceuticals at Rs 2,850 has an analyst consensus target of Rs 3,300–3,700 implying 16–30% upside. Review catalysts and risks above and consult a SEBI-registered financial advisor before investing.

Q: What are the key risks for Torrent Pharmaceuticals?

Primary risks: Germany generic price erosion on key portfolio products. Additionally: Limited US branded generic pipeline vs peers. Review the full risk analysis section for details.

Q: What is Torrent Pharmaceuticals’s market cap and P/E?

Torrent Pharmaceuticals has market cap of Rs 96,000 Cr and trailing P/E of 40x at Rs 2,850. 52-week range is Rs 2,600 to Rs 3,700.

Q: What are Torrent Pharmaceuticals’s growth catalysts?

Three key catalysts: India Branded Generic Cardiology, Germany Acquisition, and MR Expansion.

Q: What is Torrent Pharmaceuticals’s long-term target?

The Torrent Pharmaceuticals long-term share price target for FY27–28 is Rs 4,500 in the bull case — assuming consistent earnings delivery and full catalyst materialisation.

Q: Where can I track Torrent Pharmaceuticals live?

Track Torrent Pharmaceuticals (NSE: TORNTPHARM) live on the Univest Screener at univest.in/screeners. Download the Univest App for real-time alerts and SEBI-registered research.

Recent Articles

Why is Raymond’s Share Price Falling?

Why is the GACM Technologies Share Price Falling?

Why is Regaal Resources Share Price Falling?

Why is Mangalore Refinery & Petrochemicals (MRPL) Share Price Falling?

Why is All Time Plastics Share Price Falling?